Martina Amanzio (M.A.) is Associate Professor in Psychobiology at the Dept of Psychology, Univesity of Turin, Italy. M.A. is the Coordinator of the Research Group of Neuropsychology of Cognitive Impairment and Central Nervous System Degenerative Diseases. M.A. is member of the European Innovation Partnership on Active and Healthy Ageing (EIP-AHA). M.A. is research group member of the placebo responses mapping group at the Dept of Neuroscience, University of Turin, IT. At the beginning of her scientific career, during the PhD on Experimental Neuroscience, M.A. studied the field of human pain. She focused on the cerebral mechanisms of placebo analgesia, actively contributing to demonstrate the involvement of opioid neuropeptides and cholecystokinin, whilst also studying the placebo effect in terms of classical conditioning and expectancy theories. In particular, she actively learned the bases of the principal neurophysiological recording techniques, such as electromyography, abdominal reflexes and electroencephalography. She was actively involved in exciting pharmacological and clinical trials on the placebo effect. M.A. early contributions were important not only from the neurobiological and cognitive science perspectives but also for their relevant clinical implications, such as the use of placebos to reduce opioid intake in postoperative pain During her Postdoctoral Research Fellowship, she acquired competency in the use of neuropsychological methods to study cognitively impaired patients, with the collaboration of the neurology units of the Besta, San Raffaele Turro and San Raffaele hospitals, in Milan, IT. Subsequently, she gained recognition for the high integration of knowledge at the neurobiological level with the disciplines of cognitive neuroscience and she was awarded the post of Assistant Professor (2004). The experimental neuropsychological protocols M.A. developed during these years were effective and innovative, in that there were previously no tools in the literature suitable for use in patients with Alzheimer's Disease (AD) or Parkinson's Disease (PD). She carried out an in-depth investigation into the unawareness of deficits and executive dysfunction in AD and PD patients, adopting a multidisciplinary approach that combined neuropsychological and fMRI assessments to study the functioning of the cortical areas related to both phenomena. M.A. findings (i.e. Amanzio et al Brain 2011) were highlighted on the cover of this important journal. Her relevant discoveries must be considered important for guiding prognostic and therapeutic approaches and essential for diagnostic processes. For these reasons she was awarded the post of Associate Professor (2015) and her commitment was selected, from the EU, to enter in the EIP-AHA (2016). She was previously involved in the Management Committee of the European-COST-Action-TD-1005 on patients with cognitive impairment and pain conditions. M.A. research projects received attention and support with individual funding grants as PI and as member of research groups from national and international institutions. During her career M.A. published more than 40 papers on high IF journals and more than 15 book’s chapters. She obtained more than 3000 citations, with an H index of 24 and some of these papers received considerable international press attention.
Experience in neuropsychological and cerebral correlates of the progression of cognitive decline in Alzheimer’s Disease patients. Metaphor comprehension and executive dysfunction in early Alzheimer’s Disease. Unawareness of deficits and executive dysfunction in Alzheimer’s and Parkinson’s Disease. Placebo and nocebo effects from a psychophysiological and a neurocognitive perspective. In particular, Activation Likelihood Estimation meta-analysis to investigate placebo analgesia, nocebo hyperalgesia and shared “core” areas between the pain and other task related networks. Systematic reviews of adverse events in placebo groups. More recently, her specific interest has involved examining the role of neuropsychological predictors of pre-frailty conditions in cognitive healthy ageing.